
Claims

1. Compound of formula I for use in the preparation of a medicament for the prevention of dengue disease in an individual at risk of being infected by Dengue virus or for the treatment of dengue disease in an individual infected by Dengue virus, wherein the first administration of the medicament occurs prior to viral infection or prior to the time point that peak viral load in the blood is reached wherein formula I corresponds to



I

a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof; said compound is selected from the group wherein:

R_1 is H, R_2 is F and R_3 is H or CH_3,

R_1 is H, CH_3 or F, R_2 is OCH_3 and R_3 is H,

R_1 is H, R_2 is OCH_3 and R_3 is CH_3,

R_1 is CH_3, R_2 is F and R_3 is H,

R_1 is CF_3 or OCF_3, R_2 is H and R_3 is H,

R_1 is OCF_3, R_2 is OCH_3 and R_3 is H,

R_1 is OCF_3, R_2 is H and R_3 is CH_3.

2. The compound for use according to claim 1 wherein the medicament is to be administered intermittently at least once every 6 hours, at least once every 12 hours, at least once every 24 hours, at least once every week, more preferably at least once every two weeks, at least once every month, at least once every 6 months.


3. The compound for use according to any one of claims 1 to 2 wherein the medicament comprises an effective amount of compound of formula I, said effective amount is selected such that dengue virus viral load in blood is kept at a level equal to or under 15 $\log_{10}$ copies/mL, preferably equal to or under 10 $\log_{10}$ copies/mL, more preferably equal to or under 7 $\log_{10}$ copies/mL, even more preferably equal to or under 5 $\log_{10}$

copies/mL, most preferably equal to or under 3 $\log_{10}$ copies/mL, even most preferably equal to or under 2 $\log_{10}$ copies/mL .

4. The compound for use according to claim 3 wherein the effective amount of the compound is from 0.05 mg/kg to 500 mg/kg body weight.

5. The compound for use according to any one of claims 1 to 4 wherein the medicament is to be administered orally, subcutaneously, intramuscularly, or intravenously.

6. Use of a compound of formula I for the preparation of a medicament for the prevention of dengue in an individual at risk of being infected by Dengue virus or for the treatment of dengue disease in an individual infected by Dengue virus, wherein the first administration of the medicament occurs prior to viral infection or prior to the time point that peak viral load in the blood is reached wherein the formula I corresponds to



I

a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof; said compound is selected from the group wherein:

R_1 is H, R_2 is F and R_3 is H or CH_3,

R_1 is H, CH_3 or F, R_2 is OCH_3 and R_3 is H,

R_1 is H, R_2 is OCH_3 and R_3 is CH_3,

R_1 is CH_3, R_2 is F and R_3 is H,

R_1 is CF_3 or OCF_3, R_2 is H and R_3 is H,

R_1 is OCF_3, R_2 is OCH_3 and R_3 is H,

R_1 is OCF_3, R_2 is H and R_3 is CH_3.

7. The use according to claim 6, wherein the medicament is to be administered intermittently at least once every 6 hours, at least once every 12 hours, at least once every 24 hours, at least once every week, at least once every two weeks, at least once every month, at least once every 6 months.

8. The use according to any one of claims 6 to 7, wherein the medicament comprises an effective amount of compound of formula I, said effective amount is selected such that dengue virus viral load in blood is kept at a level equal to or under 15 $\log_{10}$ copies/mL, preferably equal to or under 10 $\log_{10}$ copies/mL, more preferably equal to or under 7 $\log_{10}$ copies/mL, even more preferably equal to or under 5 $\log_{10}$ copies/mL, most preferably equal to or under 3 $\log_{10}$ copies/mL, even most preferably equal to or under 2 $\log_{10}$ copies/mL.

9. The use according to any one of claims 6 to 8, wherein the effective amount of the compound is of from 0.05 mg/kg to 500 mg/kg body weight.

10. The use according to any one of claims 6 to 9, wherein the medicament is to be administered orally, subcutaneously, intramuscularly, or intravenously.